Seeking Alpha

Astellas Pharma (ALPMY.PK +1.5%) says the the FDA has approved Myrbetriq, a drug to treat adults...

Astellas Pharma (ALPMY.PK +1.5%) says the the FDA has approved Myrbetriq, a drug to treat adults with overactive bladder. The condition is one in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning. The drug relaxes the muscle and thereby relieves the symptoms.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|